Treatment with ZYKADIA may cause GI Adverse Reactions, Hepatic and Embryo-fetal Toxicities, Interstitial Lung Disease/Pneumonitis, QTc Interval Prolongation, Hyperglycemia, Bradycardia, Pancreatiti...
ZYKADIA is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
IMPORTANT SAFETY INFORMATION
Gastrointestinal Adverse Reactions
Interstitial Lung Disease/Pneumonitis
QTc Interval Prolongation
Please see full Prescribing Information.